BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,008,000 | -15.3% | 411,461 | +1.6% | 0.01% | -11.1% |
| Q2 2023 | $33,049,000 | +14.0% | 404,861 | +3.6% | 0.01% | +12.5% |
| Q1 2023 | $29,002,000 | -44.1% | 390,902 | -37.6% | 0.01% | -46.7% |
| Q4 2022 | $51,887,000 | +21.1% | 626,032 | +315.0% | 0.02% | +15.4% |
| Q3 2022 | $42,844,000 | -25.3% | 150,858 | -8.9% | 0.01% | -23.5% |
| Q2 2022 | $57,375,000 | -22.0% | 165,524 | -2.5% | 0.02% | -5.6% |
| Q1 2022 | $73,513,000 | -16.2% | 169,758 | +0.1% | 0.02% | -10.0% |
| Q4 2021 | $87,727,000 | +6.4% | 169,573 | -0.4% | 0.02% | -9.1% |
| Q3 2021 | $82,462,000 | +13.1% | 170,174 | +5.1% | 0.02% | +15.8% |
| Q2 2021 | $72,880,000 | +17.8% | 161,864 | -0.1% | 0.02% | +5.6% |
| Q1 2021 | $61,888,000 | +19.2% | 162,045 | -0.9% | 0.02% | +20.0% |
| Q4 2020 | $51,938,000 | +31.0% | 163,561 | +2.2% | 0.02% | +7.1% |
| Q3 2020 | $39,638,000 | -0.6% | 160,002 | +5.9% | 0.01% | -12.5% |
| Q2 2020 | $39,892,000 | +32.6% | 151,063 | -4.8% | 0.02% | +14.3% |
| Q1 2020 | $30,086,000 | -13.3% | 158,660 | +0.4% | 0.01% | +7.7% |
| Q4 2019 | $34,705,000 | +20.5% | 158,099 | +7.4% | 0.01% | +18.2% |
| Q3 2019 | $28,798,000 | +12.0% | 147,169 | +19.4% | 0.01% | +10.0% |
| Q2 2019 | $25,706,000 | +16.8% | 123,302 | +11.3% | 0.01% | +11.1% |
| Q1 2019 | $22,003,000 | +46.7% | 110,813 | +6.9% | 0.01% | +28.6% |
| Q4 2018 | $15,002,000 | -27.9% | 103,670 | +1.7% | 0.01% | -22.2% |
| Q3 2018 | $20,808,000 | +335.8% | 101,944 | +215.8% | 0.01% | +350.0% |
| Q2 2018 | $4,775,000 | +7.2% | 32,282 | +9.4% | 0.00% | 0.0% |
| Q1 2018 | $4,456,000 | +40.4% | 29,503 | +20.4% | 0.00% | +100.0% |
| Q4 2017 | $3,173,000 | -0.3% | 24,506 | -6.9% | 0.00% | -50.0% |
| Q3 2017 | $3,184,000 | +2.4% | 26,335 | -0.5% | 0.00% | 0.0% |
| Q2 2017 | $3,110,000 | +15.0% | 26,467 | -0.5% | 0.00% | +100.0% |
| Q1 2017 | $2,704,000 | -3.8% | 26,607 | -2.7% | 0.00% | -50.0% |
| Q4 2016 | $2,811,000 | -9.2% | 27,346 | -3.3% | 0.00% | 0.0% |
| Q3 2016 | $3,097,000 | -10.2% | 28,284 | -7.5% | 0.00% | 0.0% |
| Q2 2016 | $3,448,000 | +32.1% | 30,572 | +10.7% | 0.00% | 0.0% |
| Q1 2016 | $2,611,000 | +18.3% | 27,627 | +12.7% | 0.00% | +100.0% |
| Q4 2015 | $2,207,000 | 0.0% | 24,506 | +2.6% | 0.00% | -50.0% |
| Q3 2015 | $2,207,000 | +130.6% | 23,875 | +145.9% | 0.00% | +100.0% |
| Q2 2015 | $957,000 | +6.8% | 9,711 | +8.7% | 0.00% | 0.0% |
| Q1 2015 | $896,000 | -2.9% | 8,931 | -10.6% | 0.00% | 0.0% |
| Q4 2014 | $923,000 | – | 9,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |